<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102332">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01673360</url>
  </required_header>
  <id_info>
    <org_study_id>PR1102</org_study_id>
    <nct_id>NCT01673360</nct_id>
  </id_info>
  <brief_title>Collection of Long Term Patient Outcomes Data Following Implantation of AMS Surgical Devices</brief_title>
  <acronym>CAPTURE</acronym>
  <official_title>Collection of Long Term Patient Outcomes Data Following Implantation of AMS Surgical Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Medical Systems</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>United Kingdom: National Health Service</authority>
    <authority>Slovenia: Ethics Committee</authority>
    <authority>France: Conseil National de l'Ordre des Médecins</authority>
    <authority>France: French Data Protection Authority</authority>
    <authority>Belgium: Ethics Committee</authority>
    <authority>South Africa: Human Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To monitor post-market performance through evaluation of short and long-term performance
      via:

        -  Efficacy

        -  Safety

        -  Patient reported outcomes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As this is a post-market registry on market approved devices, there will be no formal
      hypothesis testing. However, points of evaluation will include:

        -  Characterize the efficacy of the AMS market approved female pelvic health products
           using standard of care outcome measures and validated quality of life questionnaires

        -  Characterize the type, severity, and rate of adverse events related to each AMS market
           approved female pelvic health product

        -  Collect concomitant procedural data related to the pelvic floor area
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Prolapse Efficacy - POP-Q</measure>
    <time_frame>annually, upto 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prolapse Endpoints:
• POP-Q measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Incontinence Endpoints</measure>
    <time_frame>annually upto 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urinary Incontinence Endpoints:
Cough stress test
1 hour pad weight test
Urodynamics</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Female Stress Incontinence</condition>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>Proplase Products</arm_group_label>
    <description>Subjects implanted with Elevate PC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Urinary Incontinence Group</arm_group_label>
    <description>Subjects implanted with Mini Arc Pro</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prolapse (AMS prolapse products)</intervention_name>
    <description>List of AMS prolapse products</description>
    <arm_group_label>Proplase Products</arm_group_label>
    <other_name>Elevate PC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Urinary Incontinence (Mini Arc Pro)</intervention_name>
    <description>List of AMS Urinary Incontinence devices</description>
    <arm_group_label>Urinary Incontinence Group</arm_group_label>
    <other_name>Mini Arc Pro</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients planned to receive at least one (1) target AMS market approved female pelvic
        health product will be considered for inclusion in the registry.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must meet all of the following criteria to be considered for inclusion in
             the registry.

               -  Have a signed Informed Consent Form

               -  Have a signed HIPAA Authorization Form or equivalent Patient Privacy Form if
                  required outside of the US

               -  Is a female at least 18 years of age

               -  Is scheduled to receive at least one (1) AMS market approved female pelvic
                  health implantable product.

               -  Is able and willing to participate in the registry

        Exclusion Criteria:

          -  Patients will be excluded from the registry if any one of the following criteria is
             met.

               -  Patients are contraindicated to receive the target AMS market approved female
                  pelvic health product per the product's IFU
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>CAPTURE TEAM</last_name>
    <phone>952-930-6000</phone>
    <email>capture@ammd.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atlanta Medical Research Institute</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert D Moore, DO</last_name>
      <phone>770-475-1395</phone>
      <email>moorer33@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Robert D Moore, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charbel Salamon, MD</last_name>
      <email>charbel.salamon@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Charbel Salamon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Womancare</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Miyazaki, MD</last_name>
      <phone>336-765-5470</phone>
      <email>Dmiyazaki@w-swomancare.com</email>
    </contact>
    <investigator>
      <last_name>Douglas Miyazaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seven Hills Women's Health Centers</name>
      <address>
        <city>Cinncinatti</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Karram, MD FACOG</last_name>
      <phone>513-791-6268</phone>
      <email>mkarrammd@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Michael Karram, MD FACOG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Female Pelvic Medicine Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Guerette, MD</last_name>
      <phone>804-323-2533</phone>
      <email>nlguerette@mac.com</email>
    </contact>
    <investigator>
      <last_name>Nathan Guerette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BVBA Dr. Dieter Ost</name>
      <address>
        <city>Dendermonde</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Windsor Research Office</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Biljana Basic-Panic</last_name>
      <phone>519-252-9399</phone>
      <email>bbasicpanic@yahoo.ca</email>
    </contact>
    <investigator>
      <last_name>Brad Jasey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John E Tomc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CMC Beau Soleil</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Christophe Courtieu</last_name>
      <phone>33 (0)4 67 75 97 56</phone>
      <email>c.courtieu@languedoc-mutualite.fr</email>
    </contact>
    <investigator>
      <last_name>Dr. Christophe Courtieu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital BICÊTRE</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>German Pelvic Floor Center, St. Hedwig Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>11 10115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Tunn, MD</last_name>
      <phone>+49-30-23112106</phone>
      <email>r.tunn@alexius.de</email>
    </contact>
    <investigator>
      <last_name>Prof Ralf Tunn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waldburg-Zeil Kliniken Klinik Tettnang</name>
      <address>
        <city>Tettnang</city>
        <zip>16 88069</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Fünfgeld, MD</last_name>
      <phone>0049 7542 531 301</phone>
      <email>christian.fuenfgeld@t-online.de</email>
    </contact>
    <investigator>
      <last_name>Christian Fünfgeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Maribor</name>
      <address>
        <city>Maribor</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pretoria Urology Hospital</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico y Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eduardo Bataller, MD</last_name>
      <phone>34932275534</phone>
      <email>ebatalle@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Eduardo Bataller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Beata María Ana de Jesus</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregorio Escribano, MD</last_name>
      <phone>+0034914097557</phone>
      <email>gescribano@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Gregorio Escribano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Maria Martinez-Sagarra, MD PhD</last_name>
      <phone>+0034 983 420400</phone>
      <email>jmmso@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Carlos Marina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Maria Martinez-Sagarra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Bolton Hospital</name>
      <address>
        <city>Bolton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Chia, MD</last_name>
      <phone>00441204390954</phone>
      <email>Phil.chia@rbh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Philip Chia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glasgow - Southern General Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Guerrero, MD</last_name>
      <phone>+44 141 2012237</phone>
      <email>Karen.guerrero@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Hassan Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Guerrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 18, 2012</lastchanged_date>
  <firstreceived_date>August 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaginal repair</keyword>
  <keyword>urinary slings</keyword>
  <keyword>POP</keyword>
  <keyword>SUI</keyword>
  <keyword>prolapse</keyword>
  <keyword>incontinence</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
